Search research articles
Contact Us
Filters
Showing results (91-100 of 166) with videos related to
Page
of 17
Sort By:
Pharmaceutics
|
April 23, 2022
Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
Eric D Eisenmann, Dominique A Garrison, Zahra Talebi, et al.
Cancer Research
|
January 21, 2006
Ductal access for prevention and therapy of mammary tumors
Satoshi Murata, Scott L Kominsky, Mustafa Vali, et al.
Blood
|
September 19, 2013
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
Eric I Zimmerman, David C Turner, Jassada Buaboonnam, et al.
American Journal of Clinical Oncology
|
August 8, 2006
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma
Victoria J Sinibaldi, Kathy Elza-Brown, Jill Schmidt, et al.
Blood Advances
|
July 7, 2022
BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
Daelynn R Buelow, Bhavana Bhatnagar, Shelley J Orwick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2006
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors
Wells A Messersmith, Sharyn D Baker, Lance Lassiter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2002
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies
Johann S de Bono, Joseph Stephenson, Sharyn D Baker, et al.
Cancer Research Communications
|
December 24, 2021
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition
Eric D Eisenmann, Qiang Fu, Elizabeth M Muhowski, et al.
Investigational New Drugs
|
March 23, 2010
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer
Colin D Weekes, Sujatha Nallapareddy, Michelle A Rudek, et al.
Cancer Chemotherapy and Pharmacology
|
June 1, 2010
Marginal increase of sunitinib exposure by grapefruit juice
Nielka P van Erp, Sharyn D Baker, Anthe S Zandvliet, et al.
Page
of 17
Search research articles
Search
Showing results (91-100 of 166) with videos related to
Sort By:
Page
of 17
Pharmaceutics
|
April 23, 2022
Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
Eric D Eisenmann, Dominique A Garrison, Zahra Talebi, et al.
Cancer Research
|
January 21, 2006
Ductal access for prevention and therapy of mammary tumors
Satoshi Murata, Scott L Kominsky, Mustafa Vali, et al.
Blood
|
September 19, 2013
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia
Eric I Zimmerman, David C Turner, Jassada Buaboonnam, et al.
American Journal of Clinical Oncology
|
August 8, 2006
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma
Victoria J Sinibaldi, Kathy Elza-Brown, Jill Schmidt, et al.
Blood Advances
|
July 7, 2022
BMX kinase mediates gilteritinib resistance in FLT3-mutated AML through microenvironmental factors
Daelynn R Buelow, Bhavana Bhatnagar, Shelley J Orwick, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 21, 2006
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors
Wells A Messersmith, Sharyn D Baker, Lance Lassiter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 5, 2002
Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies
Johann S de Bono, Joseph Stephenson, Sharyn D Baker, et al.
Cancer Research Communications
|
December 24, 2021
Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition
Eric D Eisenmann, Qiang Fu, Elizabeth M Muhowski, et al.
Investigational New Drugs
|
March 23, 2010
Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer
Colin D Weekes, Sujatha Nallapareddy, Michelle A Rudek, et al.
Cancer Chemotherapy and Pharmacology
|
June 1, 2010
Marginal increase of sunitinib exposure by grapefruit juice
Nielka P van Erp, Sharyn D Baker, Anthe S Zandvliet, et al.
Page
of 17